Lepton Pharmaceutical announces that on February 10, 2021 it entered into a Master Service Agreement with Axolabs GMBH, Kulmbach Germany. Pursuant to the agreement, Axolabs shall provide to Lepton Pharmaceutical chemical laboratory services for Lepton’s pipeline in development by directly targeting immunological drivers of diseases. Axolabs is a leading custom research organization providing high-end preclinical solutions and consultancy in the field of oligonucleotide therapeutics and nucleic acid medicines.